Clinical trials
Phase 3 trials in Kuwait
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Unknown status | 3 |
| Terminated | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 4 |
| Hoffmann-La Roche | 3 |
| Kuwait Cancer Control Center | 2 |
| AstraZeneca | 1 |
| Dr. Reddy's Laboratories Limited | 1 |
| Hamid Al-Essa Organ Transplant Center | 1 |
| King Faisal Specialist Hospital & Research Center | 1 |
| McMaster University | 1 |
| Novartis Pharmaceuticals | 1 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis, Relapsing-Remitting | 5 |
| Diabetes Mellitus, Type 2 | 2 |
| Multiple Sclerosis | 2 |
| Nasopharyngeal Carcinoma | 2 |
| Acute Coronary Syndrome | 1 |
| Breast Neoplasms | 1 |
| COVID-19 | 1 |
| Diabetes Mellitus | 1 |
| Gastrointestinal Hemorrhage | 1 |
| Glucose Metabolism Disorders | 1 |
Trials
Showing 26 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.